TABLE 2.
Summary of data from relevant lncRNAs-based biomarkers in human multiple tumors.
| Biomarkers | Dys-regulation | Tumors | Sample type | Sample size | Technological approach | Application | Comments | References |
|---|---|---|---|---|---|---|---|---|
| LncRNA-ATB FAM83H-AS1 | Up | Breast cancer | Serum | 90 breast cancer patients | RT-PCR | Prognosis; disease monitoring | Serum lncRNA-ATB and FAM83H-AS1 could be used as a non-invasive diagnostic marker for early stages of breast cancer | El-Ashmawy et al. (2020) |
| LINC00114, LINC00261, HOTAIR | HOTAIR (Up), LINC00114 and LINC00261 (Down) | CRC | Tissues | 459 nonmetastatic CRC samples and 87 metastatic CRC samples | RT-PCR | Prognosis; disease monitoring | 3-lncRNA signature that includes LINC00114, LINC00261, and HOTAIR is an independent factor for predicting CRC prognosis | Liu et al. (2020) |
| MSC-AS1 | Up | LC | Tissues | 123 LC patients (111 tumor | — | — | — | — |
| tissues, 12 adjacent normal samples) | RT-PCR | Diagnosis and prognosis | MSC-AS1 may be used as a potential biomarker of LC. | Liu et al. (2021b) | — | — | — | — |
| HELIS LINC01093, CYTOR | HELIS and LINC01093 (Down), CYTOR (Up) | HCC | Tissues | 82 paired tissue samples from patients with HCC | RT-PCR | Prognosis; disease monitoring | Down-regulated HELIS and LINC01093, up-regulated CYTOR are perspectives for differential diagnostics of HCC | Burenina et al. (2021) |
| SNHG18 | Up | HCC | Tissues, Plasma | 71 paired HCC patients | RT-PCR | Diagnosis | — | — |
| DLG2-AS1 | Down | LUAD | Tissues | 70 LUAD patients | RT-PCR | Prognosis; disease monitoring | DLG2-AS1 serves as a good diagnostic biomarker for LUAD patients | Arenas et al. (2020) |
| MIAT, LINC00460, and LINC00443 | MIAT and LINC00460 (Up) LINC00443 (Down) | KIRC | Tissues | 530 KIRC patients | RT-PCR | Prognosis; disease monitoring | The LPM based on three-lncRNAs could serve as independent prognostic factors with a tremendous predictive ability for KIRC patients | Zhang et al. (2020a) |
| SAMMSON | Up | OSCC, GBM | Tissues, Plasma | 90 OSCC patients | — | — | — | — |
| 56 patients with GBM (34 males and 22 females) | RT-PCR | Diagnosis and prognosis | SAMMSON might play a critical role in OSCC progression and serve as a novel prognostic and diagnostic biomarker in OSCC. | — | — | — | — | — |
| Plasma SAMMSON has diagnostic value for GBM | Xie et al. (2019); Zheng et al. (2020) | — | — | — | — | — | — | — |
| LUCAT1 | Up | PTC | Tissues | 61 PTC patients | RT-PCR | Diagnosis and prognosis | LUCAT1 can act as a novel prognostic biomarker for patients with PTC | Luzón-Toro et al. (2019) |
| PTENP1 | Down | BC | Plasma | 50 patients with BC and 60 healthy controls | RT-PCR | Diagnosis | Exosomal PTENP1 is a potential novel biomarker that can be used for the clinical detection of BC. | Zheng et al. (2018) |
| PANDAR, FOXD2-AS1, SMARCC2 | Up | GC | Plasma | 109 GC patients and 106 healthy controls | RT-PCR | Diagnosis | Plasma PANDAR, FOXD2-AS1, and SMARCC2 may be appropriate diagnostic biomarkers for GC. | Yang et al. (2019b) |